Disclosures pursuant to Rule 12(9) of Companies (Share Capital and Debentures) Rules, 2019 and Regulation 14 read with Part F of Schedule I of the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 on ESOP read with SEBI Circular dated June 6, 2015 for the Financial year 2022-2023

	weat Equity) Regulations, 2021 on ESOP 1 ancial year 2022-2023	read with SEBI Circular dated June 6, 2015 for the				
FIII		na 2023 ("the Scheme") is in compliance with SERI				
	The Netweb Employees Stock Option Scheme, 2023 ("the Scheme") is in compliance with SEB (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.					
A	Relevant disclosures in terms of the accounting standards prescribed by the Central Government in terms of section 133 of the Companies Act, 2013 (18 of 2013) including the 'Guidance note on accounting for employee share-based payments' issued in this regard from time to time	Details have been provided in the Notes to Accounts of the Financial Statements in the Annual report 2023-24 as Note no 52.				
В	Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations shall be disclosed in accordance with 'Accounting Standard 20 - Earnings Per Share' issued by ICAI or any other relevant accounting standards as prescribed from time to time	Diluted EPS for the financial year 2023-24 as per AS-20 of ICAI is Rs. 13.88 per share.				
C	Details related to ESOS					
(i)	A description of each ESOS that existed at any time during the year, including the general terms					
	and conditions of each ESOS, including					
	(a) Date of shareholders' approval	January 09, 2023 with further revision on February 23, 2023				
	(b) Total number of options approved under ESOP Scheme	25,46,199				
	(c) Vesting requirements	1-3 years (3 years from the date of grant (February 1, 2023) in three equal instalments starting from the date of grant.				
	(d) Exercise price or pricing formula	Rs. 2/- per share				
	(e) Maximum term of options granted (Exercise period)	1-3 years				
	(f) Source of shares (primary, secondary or combination)	Primary				
	(g) Variation in terms of options	Nil				
(ii)	Method used to account for ESOS -	Fair Value				
	Intrinsic or fair value.					
(ii)	Where the company opts for the expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the	N.A.				

	fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the company shall also be disclosed.				
(IV)	Option movement during the year				
		Particulars		Details	
		Number of options outs	_	9,05,472	
		at the beginning of the period  Number of options granted			
				-	
		during the year			
		Number of options forfeited /		-	
		lapsed during the year			
		Number of options vested		3,01,824	
		during the year			
		Number of options exe		3,00,888	
		during the year			
		Number of shares arising as a result of exercise of options  Money realized by exercise of options (INR)  Variation of Terms of Options  Number of options outstanding at the end of the year		3,00,888	
				6,01,776	
				Nil	
				6,04,584	
		Number of options exercisable		936	
		at the end of the year			
(v)	Weighted-average exercise prices and				
	weighted-average fair values of options	Weighted average exercise price of options			
	shall be disclosed separately for options	granted during the year whose			
	whose exercise price either equals or	Details of Esop	+	heme 2023	
	exceeds or is less than the market price of the stock.	Exercise price Equals	NA		
	che stock.	to Market Price	NT A		
		Exercise price	NA		
		exceeds Market Price	NI A		
		Exercise price Less than Market Price	NA		
			in volu	of ontions	
		Weighted average fair value of options granted during the year whose			
		Exercise price Equals NA			
		to Market Price	INA		
		Exercise price	NA		
		exceeds Market Price	1111		
		Exercise price Less	NA		
		than Market Price	1 17 1		
	<u> </u>	man market i file			

(vi) Employee wise details (name of employee, designation, number of options granted during the year, exercise price) of options granted to

No options were granted during the financial year 2023-24. The options were granted during the financial year 2022-23 which were vested and exercised during the FY 2023-24.

- (a) Key Managerial personnel/senior managerial personnel as defined under Regulation 16(d) of the SEBI (LODR) Regulations,2015
- (b) any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year;
- (c) identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant.

No options were granted during the year.

- (vii) A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information
  - (a) the weighted-average values of share price, exercise price, expected volatility, expected option life, expected dividends, the risk-free interest rate and any other inputs to the model; used and (b) the method the assumptions made to incorporate the effects of expected early exercise; how expected volatility (c) determined, including an explanation of the extent to which expected volatility
  - was based on historical volatility; and (d) whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition.

## Disclosures in respect of grants made in three years prior to IPO under each ESOS

The Scheme was approved by the shareholders in FY 2022-23 on 09.01.2023 further revised on 23.02.2023. So far, 905472 options have been granted out of the total 25,46,199 pool of options.